NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal
This article was originally published in The Pink Sheet Daily
The privately-held biotech chooses a different commercial path for its proprietary product and gains validation for its nano-emulsion delivery platform, NanoStat.
You may also be interested in...
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.